Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Those with existing cardiovascular conditions should be especially cautious and consult a provider before beginning treatment
Texas Screening Alliance for Cancer Therapeutics, 2012
Lancet 2021;398:143-155
The SELECT trial with injected semaglutide demonstrated a 20% reduction in the frequency of 3-point MACE outcome in people with preexisting CVD and overweight/obesity without T2D [6], and injected semaglutide has been shown to reduce 3-point MACE outcomes by 26% in patients with pre-existing CVD and T2D [7]
Yet most patients were left to figure it out alone
US$ 26.46
US$ 20.23
US$ 24.85
